

David M Margolis

List of Publications by Citations

Source: <https://exaly.com/author-pdf/341668/david-m-margolis-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

206
papers

15,847
citations

66
h-index

121
g-index

233
ext. papers

18,831
ext. citations

9.4
avg, IF

6.47
L-index

#	Paper	IF	Citations
206	Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. <i>Nature</i> , 2012 , 487, 482-5	50.4	844
205	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. <i>Cell</i> , 2020 , 182, 429-446.e14	56.2	710
204	The challenge of finding a cure for HIV infection. <i>Science</i> , 2009 , 323, 1304-7	33.3	682
203	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. <i>Science</i> , 2020 , 370, 1464-1468	33.3	517
202	Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. <i>Lancet, The</i> , 2005 , 366, 549-55	40	454
201	The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. <i>Science Immunology</i> , 2020 , 5,	28	450
200	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012 , 12, 607-14	36.5	414
199	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016 , 22, 839-50	50.5	303
198	Inhibition of HIV fusion with multivalent gold nanoparticles. <i>Journal of the American Chemical Society</i> , 2008 , 130, 6896-7	16.4	294
197	The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. <i>Journal of Virology</i> , 2000 , 74, 6790-9	6.6	291
196	An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. <i>PLoS Pathogens</i> , 2013 , 9, e1003834	7.6	283
195	Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 207-12	1.6	282
194	Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. <i>Journal of Infectious Diseases</i> , 2015 , 212, 1361-5	7	252
193	The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. <i>PLoS Medicine</i> , 2010 , 7, e1000321	11.6	222
192	Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. <i>Journal of Infectious Diseases</i> , 1990 , 162, 723-6	7	219
191	Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. <i>Aids</i> , 2004 , 18, 1101-8	3.5	208
190	Eradicating HIV-1 infection: seeking to clear a persistent pathogen. <i>Nature Reviews Microbiology</i> , 2014 , 12, 750-64	22.2	202

189	Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. <i>Molecular and Cellular Biology</i> , 2002 , 22, 2965-73	4.8	201
188	BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. <i>Journal of Leukocyte Biology</i> , 2012 , 92, 1147-54	6.5	194
187	Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. <i>Journal of Virology</i> , 2011 , 85, 9078-89	6.6	193
186	HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. <i>Journal of Infectious Diseases</i> , 2014 , 210, 728-35	7	191
185	c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. <i>Journal of Virology</i> , 2007 , 81, 10914-23	6.6	183
184	HIV reservoirs: what, where and how to target them. <i>Nature Reviews Microbiology</i> , 2016 , 14, 55-60	22.2	176
183	Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 9523-8	11.5	170
182	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. <i>Journal of Experimental Medicine</i> , 2011 , 208, 2237-49	16.6	166
181	Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. <i>Neurology</i> , 2010 , 74, 1260-6	6.5	166
180	Latency reversal and viral clearance to cure HIV-1. <i>Science</i> , 2016 , 353, aaf6517	33.3	159
179	A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. <i>Journal of Virology</i> , 2009 , 83, 4749-56	6.6	156
178	Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. <i>Journal of Virology</i> , 2011 , 85, 6060-4	6.6	155
177	Generation of HIV latency in humanized BLT mice. <i>Journal of Virology</i> , 2012 , 86, 630-4	6.6	155
176	Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. <i>Aids</i> , 2008 , 22, 1131-5	3.5	143
175	Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. <i>Aids</i> , 2009 , 23, 1799-806	3.5	137
174	Evidence of dysregulation of dendritic cells in primary HIV infection. <i>Blood</i> , 2010 , 116, 3839-52	2.2	137
173	Emerging strategies to deplete the HIV reservoir. <i>Current Opinion in Infectious Diseases</i> , 2014 , 27, 29-35	5.4	130
172	Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. <i>PLoS Medicine</i> , 2009 , 6, e1000107	11.6	129

171	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. <i>Blood</i> , 2016 , 128, 2561-2567	2.2	123
170	Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 3111-6	11.5	123
169	Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. <i>PLoS ONE</i> , 2010 , 5, e9390	3.7	123
168	Snapshots: chromatin control of viral infection. <i>Virology</i> , 2013 , 435, 141-56	3.6	116
167	Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. <i>Journal of Clinical Investigation</i> , 2017 , 127, 3126-3135	15.9	111
166	Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. <i>Journal of Virology</i> , 2014 , 88, 14070-7	6.6	110
165	Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. <i>Journal of Clinical Investigation</i> , 2015 , 125, 4077-90	15.9	104
164	Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 13812-7	11.5	103
163	Systemic HIV and SIV latency reversal via non-canonical NF- κ B signalling in vivo. <i>Nature</i> , 2020 , 578, 160-165	5.4	102
162	Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN- γ -producing and partially matured phenotype. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1088-101	15.9	102
161	Histone deacetylase inhibitors and HIV latency. <i>Current Opinion in HIV and AIDS</i> , 2011 , 6, 25-9	4.2	96
160	Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation. <i>Retrovirology</i> , 2013 , 10, 119	3.6	88
159	No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 229-35	3.1	87
158	Targeted cytotoxic therapy kills persisting HIV infected cells during ART. <i>PLoS Pathogens</i> , 2014 , 10, e1003872	3.872	85
157	Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 21, 362	3.1	84
156	Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. <i>Virology</i> , 1992 , 186, 788-91	3.6	81
155	Atazanavir for the treatment of human immunodeficiency virus infection. <i>Pharmacotherapy</i> , 2004 , 24, 1732-47	5.8	78
154	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , 2018 , 218, 1954-1963	7	77

153	Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. <i>Pediatrics</i> , 2003 , 112, 66-73	7.4	76
152	Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degradator. <i>Cell Chemical Biology</i> , 2020 , 27, 47-56.e15	8.2	74
151	Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. <i>Journal of Virology</i> , 2011 , 85, 5220-3	6.6	72
150	Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. <i>Journal of Infectious Diseases</i> , 2015 , 212, 258-63	7	71
149	Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8 cells. <i>Nature</i> , 2020 , 578, 154-159	50.4	70
148	Mechanisms of HIV latency: an emerging picture of complexity. <i>Current HIV/AIDS Reports</i> , 2010 , 7, 37-43	5.9	70
147	Prospects for treatment of latent HIV. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 93, 46-56	6.1	68
146	Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse. <i>Journal of Virology</i> , 2009 , 83, 8254-8	6.6	68
145	Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 806-14	27.4	68
144	Latent HIV-1 infection of resting CD4+ T cells in the humanized Rag2 ^{+/+} γ ^{+/+} mouse. <i>Journal of Virology</i> , 2012 , 86, 114-20	6.6	67
143	The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	66
142	Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1162-70	7	66
141	IL-2 receptor β chain molecule is critical for intestinal T-cell reconstitution in humanized mice. <i>Mucosal Immunology</i> , 2012 , 5, 555-66	9.2	65
140	The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 31, 45-9	3.1	65
139	Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. <i>Journal of Virology</i> , 2002 , 76, 12349-54	6.6	64
138	Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. <i>Antiviral Research</i> , 2002 , 55, 41-52	10.8	62
137	Curing HIV: Pharmacologic approaches to target HIV-1 latency. <i>Annual Review of Pharmacology and Toxicology</i> , 2011 , 51, 397-418	17.9	61
136	HIV latency is reversed by ACS2-driven histone crotonylation. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1190-1198	15.9	59

135	Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. <i>PLoS ONE</i> , 2011 , 6, e19617	3.7	58
134	Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 72, 31-8	3.1	58
133	Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal. <i>Journal of Virology</i> , 2018 , 92,	6.6	56
132	Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. <i>Journal of Infectious Diseases</i> , 2007 , 195, 1426-36	7	55
131	Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. <i>Journal of Infectious Diseases</i> , 1993 , 167, 1045-52	7	54
130	Digital necrosis and disseminated <i>Pneumocystis carinii</i> infection after aerosolized pentamidine prophylaxis. <i>Annals of Internal Medicine</i> , 1989 , 111, 681-2	8	53
129	Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. <i>Journal of Infectious Diseases</i> , 2015 , 211, 780-90	7	52
128	HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. <i>Retrovirology</i> , 2013 , 10, 121	3.6	52
127	Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. <i>Journal of Infectious Diseases</i> , 2004 , 190, 1429-37	7	52
126	A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 423-34	3.1	52
125	Combined approaches for HIV cure. <i>Current Opinion in HIV and AIDS</i> , 2013 , 8, 230-5	4.2	51
124	Prevalence of pressure ulcers on hospital admission among nursing home residents transferred to the hospital. <i>Wound Repair and Regeneration</i> , 2008 , 16, 331-6	3.6	51
123	Noninvasive evaluation of liver metabolism by 2H and 13C NMR isotopomer analysis of human urine. <i>Analytical Biochemistry</i> , 2003 , 312, 228-34	3.1	51
122	Selective HDAC inhibition for the disruption of latent HIV-1 infection. <i>PLoS ONE</i> , 2014 , 9, e102684	3.7	51
121	Peripheral VβVβ T Cells Are a Novel Reservoir of Latent HIV Infection. <i>PLoS Pathogens</i> , 2015 , 11, e1005206	3.6	50
120	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , 2020 , 181, 189-206	56.2	48
119	Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. <i>Cell Reports</i> , 2017 , 18, 1324-1334	10.6	47
118	Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. <i>Blood</i> , 2017 , 129, 2308-2315	2.2	47

117	Gold nanoparticles to improve HIV drug delivery. <i>Future Medicinal Chemistry</i> , 2015 , 7, 1097-107	4.1	47
116	The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function. <i>Scientific Reports</i> , 2016 , 6, 30749	4.9	47
115	HIV antibodies for treatment of HIV infection. <i>Immunological Reviews</i> , 2017 , 275, 313-323	11.3	46
114	Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients. <i>Supportive Care in Cancer</i> , 2012 , 20, 1405-15	3.9	46
113	Framing expectations in early HIV cure research. <i>Trends in Microbiology</i> , 2014 , 22, 547-9	12.4	45
112	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. <i>JCI Insight</i> , 2017 , 2,	9.9	45
111	Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. <i>Cell Reports</i> , 2018 , 25, 107-117.e3	10.6	45
110	Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, 505-8	3.1	44
109	The regulation of HIV-1 gene expression: the emerging role of chromatin. <i>DNA and Cell Biology</i> , 2002 , 21, 697-705	3.6	44
108	H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells. <i>Journal of Virology</i> , 2015 , 89, 8392-405	6.6	43
107	Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. <i>Journal of Infectious Diseases</i> , 2009 , 199, 866-71	7	43
106	A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. <i>HIV Medicine</i> , 2006 , 7, 317-22	2.7	43
105	Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. <i>Journal of Infectious Diseases</i> , 2017 , 215, S111-S118	7	41
104	In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. <i>Retrovirology</i> , 2016 , 13, 36	3.6	41
103	Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. <i>Antiviral Chemistry and Chemotherapy</i> , 2014 , 23, 145-9	3.5	41
102	Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 823-834	64.1	41
101	HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4074-4085	15.9	40
100	Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. <i>Journal of Virology</i> , 2006 , 80, 4570-9	6.6	38

99	HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. <i>Frontiers in Immunology</i> , 2016 , 7, 356	8.4	38
98	Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999 , 21, 362		37
97	Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. <i>Molecular Therapy</i> , 2015 , 23, 387-95	11.7	36
96	Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. <i>Journal of Virus Eradication</i> , 2017 , 3, 82-84	2.8	36
95	HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. <i>Journal of Virology</i> , 2014 , 88, 3340-52	6.6	36
94	Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. <i>Journal of Infectious Diseases</i> , 2006 , 194, 1677-85	7	34
93	Words matter: Discussing research towards an HIV cure in research and clinical contexts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, e110-1	3.1	33
92	Effect of the weaver (wv) mutation on cerebellar neuron differentiation. I. Qualitative observations of neuron behavior in culture. <i>Developmental Biology</i> , 1985 , 107, 156-72	3.1	33
91	Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 111-122	1.6	32
90	Acute HIV-1 infection in the Southeastern United States: a cohort study. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 121-8	1.6	31
89	Eradication therapies for HIV Infection: time to begin again. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 347-53	1.6	31
88	CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020 , 26, 519-528	50.5	30
87	Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 36, 1103-4	3.1	30
86	Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2008 , 47, 421-4	11.6	28
85	HSV-1 activation of HIV-1 transcription is augmented by a cellular protein that binds near the initiator element. <i>Virology</i> , 1993 , 192, 370-4	3.6	28
84	New Frontiers in Measuring and Characterizing the HIV Reservoir. <i>Frontiers in Microbiology</i> , 2019 , 10, 2878	5.7	28
83	Pharmaceutical approaches to eradication of persistent HIV infection. <i>Expert Reviews in Molecular Medicine</i> , 2009 , 11, e6	6.7	27
82	Abacavir in Combination With the Inosine Monophosphate Dehydrogenase (IMPDH) Inhibitor Mycophenolic Acid Is Active Against Multidrug-Resistant HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 22, 406	3.1	27

81	Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. <i>EBioMedicine</i> , 2017 , 23, 52-58	8.8	25
80	Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. <i>HIV Medicine</i> , 2006 , 7, 530-6	2.7	25
79	Chromatin Regulation and the Histone Code in HIV Latency?. <i>Yale Journal of Biology and Medicine</i> , 2017 , 90, 229-243	2.4	25
78	Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency. <i>Antiviral Research</i> , 2015 , 123, 78-85	10.8	23
77	Glucose production pathways by 2H and 13C NMR in patients with HIV-associated lipodystrophy. <i>Magnetic Resonance in Medicine</i> , 2004 , 51, 649-54	4.4	23
76	How Might We Cure HIV?. <i>Current Infectious Disease Reports</i> , 2014 , 16, 392	3.9	22
75	Characterizing the Switching Thresholds of Magnetophoretic Transistors. <i>Advanced Materials</i> , 2015 , 27, 6176-80	24	22
74	Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. <i>Aids</i> , 2011 , 25, 941-9	3.5	22
73	Effect of the weaver (wv) mutation on cerebellar neuron differentiation. II. Quantitation of neuron behavior in culture. <i>Developmental Biology</i> , 1985 , 107, 173-9	3.1	21
72	Ten Years of Screening and Testing for Acute HIV Infection in North Carolina. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 111-9	3.1	20
71	Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model. <i>PLoS Pathogens</i> , 2016 , 12, e1006026	7.6	20
70	The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. <i>Aids</i> , 2007 , 21, 2025-32	3.5	19
69	A Pilot Study of the Use of Mycophenolate Mofetil as a Component of Therapy for Multidrug-Resistant HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 423-434	3.1	19
68	Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 22, 406-7	3.1	19
67	Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. <i>Antiviral Therapy</i> , 2013 , 18, 39-43	1.6	18
66	Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter. <i>Journal of Virology</i> , 2005 , 79, 5952-62	6.6	18
65	HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. <i>Molecular Therapy</i> , 2018 , 26, 2496-2506	11.7	18
64	HIV Persistence on Antiretroviral Therapy and Barriers to a Cure. <i>Advances in Experimental Medicine and Biology</i> , 2018 , 1075, 165-185	3.6	17

63	Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 74, 221-228	3.1	17
62	SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. <i>Journal of Virology</i> , 2020 , 94,	6.6	17
61	Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells. <i>Aids</i> , 2015 , 29, 2235-44	3.5	16
60	Neuronal differentiation in cultures of weaver (wv) mutant mouse cerebellum. <i>Journal of Supramolecular Structure and Cellular Biochemistry</i> , 1981 , 17, 79-86		16
59	Multi-omics analyses reveal that HIV-1 alters CD4 T cell immunometabolism to fuel virus replication. <i>Nature Immunology</i> , 2021 , 22, 423-433	19.1	16
58	Ex vivo modeling of the effects of mycophenolic acid on HIV infection: considerations for antiviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 116-24	1.6	14
57	A cutaneous lesion in a patient with AIDS: an unusual presentation of infection due to <i>Mycobacterium avium</i> complex. <i>Clinical Infectious Diseases</i> , 1993 , 16, 555-7	11.6	14
56	T cells: an immunotherapeutic approach for HIV cure strategies. <i>JCI Insight</i> , 2018 , 3,	9.9	14
55	Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. <i>Scientific Reports</i> , 2020 , 10, 5134	4.9	13
54	In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. <i>Aids</i> , 2019 , 33, 605-613	3.5	13
53	HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths. <i>Molecular Therapy</i> , 2018 , 26, 1435-1446	11.7	12
52	HIV/AIDS. Persistence by proliferation?. <i>Science</i> , 2014 , 345, 143-4	33.3	12
51	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5157-5170	15.9	12
50	HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019 , 15, 9-17	6.4	11
49	Therapy for persistent HIV. <i>Trends in Pharmacological Sciences</i> , 2010 , 31, 206-11	13.2	11
48	Confronting proviral HIV infection. <i>Current HIV/AIDS Reports</i> , 2007 , 4, 60-4	5.9	11
47	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. <i>Journal of Virology</i> , 2021 , 95,	6.6	11
46	Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. <i>MSphere</i> , 2021 , 6, e0027521	5	11

45	Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 2006 , 21, 362		10
44	Attacking HIV provirus: therapeutic strategies to disrupt persistent infection. <i>Infectious Disorders - Drug Targets</i> , 2006 , 6, 369-76	1.1	10
43	Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1843-1852	7	9
42	How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?. <i>Journal of Infectious Diseases</i> , 2019 , 220, S24-S26	7	9
41	Selective targeting of the repressive transcription factors YY1 and cMyc to disrupt quiescent human immunodeficiency viruses. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 289-98	1.6	9
40	The HIV-1 latent reservoir is largely sensitive to circulating T cells. <i>ELife</i> , 2020 , 9,	8.9	9
39	Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021 , 224, 92-100	7	9
38	Measuring the Inducible, Replication-Competent HIV Reservoir Using an Ultra-Sensitive p24 Readout, the Digital ELISA Viral Outgrowth Assay. <i>Frontiers in Immunology</i> , 2020 , 11, 1971	8.4	8
37	Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals 2021 ,		8
36	CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques. <i>Journal of Virology</i> , 2021 ,	6.6	8
35	Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. <i>JCI Insight</i> , 2018 , 3,	9.9	8
34	Translational challenges in targeting latent HIV infection and the CNS reservoir problem. <i>Journal of NeuroVirology</i> , 2015 , 21, 222-6	3.9	7
33	Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). <i>Aids</i> , 2012 , 26, 1452	3.5	7
32	Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). <i>Aids</i> , 2012 , 26, 1-9	3.5	7
31	Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 49, 377-83	3.1	7
30	CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 1047-66	1.6	7
29	Inhibition of HIV Replication by A77 1726, the Active Metabolite of Leflunomide, in Combination With Pyrimidine Nucleoside Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 28, 199-201	3.1	7
28	The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing Agent		7

27	Detection of human immunodeficiency virus RNAs in living cells using Spinach RNA aptamers. <i>Virus Research</i> , 2017 , 228, 141-146	6.4	6
26	Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA. <i>Journal of Virus Eradication</i> , 2016 , 2, 57-65	2.8	6
25	Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal. <i>ACS Infectious Diseases</i> , 2020 , 6, 1719-1733	5.5	6
24	Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. <i>HIV Clinical Trials</i> , 2003 , 4, 231-43		6
23	Epigenomic characterization of latent HIV infection identifies latency regulating transcription factors. <i>PLoS Pathogens</i> , 2021 , 17, e1009346	7.6	6
22	Eliminating persistent HIV infection: getting to the end of the rainbow. <i>Journal of Infectious Diseases</i> , 2007 , 195, 1734-6	7	5
21	A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. <i>AIDS Research and Therapy</i> , 2006 , 3, 16	3	5
20	Attacking latent HIV provirus: from mechanism to therapeutic strategies. <i>Current Opinion in HIV and AIDS</i> , 2006 , 1, 134-40	4.2	5
19	Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. <i>Aids</i> , 2016 , 30, 2815-2822	3.5	4
18	Change-point models to estimate the limit of detection. <i>Statistics in Medicine</i> , 2013 , 32, 4995-5007	2.3	4
17	Countering HIV - Three@ the Charm?. <i>New England Journal of Medicine</i> , 2018 , 378, 295-297	59.2	3
16	Treatment for lipoatrophy: facing the real costs. <i>Aids</i> , 2007 , 21, 1819-20	3.5	3
15	Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA. <i>Journal of Virus Eradication</i> , 2016 , 2, 57-65	2.8	3
14	Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. <i>Aids</i> , 2020 , 34, 1923-1931	3.5	3
13	Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. <i>Aids</i> , 2021 , 35, 2225-2227	3.5	3
12	Discovery of a large-scale, cell-state-responsive allosteric switch in the 7SK RNA using DANCE-MaP.. <i>Molecular Cell</i> , 2022 ,	17.6	3
11	Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52.. <i>IScience</i> , 2022 , 25, 103649	6.1	2
10	Four Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May be Attributed to Rectal Swab Use. <i>Pathogens and Immunity</i> , 2019 , 4, 235-250	4.9	2

9	Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat. <i>Journal of Virology</i> , 2020 , 94,	6.6	2
8	Reply to Cooper et al. <i>Journal of Infectious Diseases</i> , 2008 , 197, 775-776	7	1
7	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1528-1531	11.6	1
6	Measuring the Haystack Needles. <i>Journal of Infectious Diseases</i> , 2021 , 223, 184-186	7	0
5	Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART Molecules. <i>Frontiers in Immunology</i> , 2021 , 12, 710273	8.4	0
4	Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque Infants.. <i>Journal of Virology</i> , 2022 , e0169921	6.6	0
3	Latency Reversal and Clearance of Persistent HIV Infection.. <i>Methods in Molecular Biology</i> , 2022 , 2407, 375-389	1.4	
2	Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA. <i>Journal of Virus Eradication</i> , 2020 , 6, 85-95	2.8	
1	Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA. <i>Journal of Virus Eradication</i> , 2018 , 4, 132-142	2.8	